How is European pharma responding to stricter transparency laws? | Pharmaceutics_R&D |
This article is about promotional compliance trends in Europe following the lead of anti-bribery and anti-corruption laws set in the United States.

In this article, we look at European pharma promotional compliance trends as reported in Cegedim Relationship Management’s third annual survey: ‘2012 European Trends in Aggregate Spend, Transparency, and Disclosure’.

The pharmaceutical, medical device and biotech industries are currently witnessing the rise of tighter promotional transparency regulations. As many expected, the stringency of anti-corruption and anti-bribery laws already in place in the United States are beginning to make their way over to Europe, with some countries in Europe already surpassing the enforcement levels set by the US. (...) - by Hannah Blake, pharmaphorum5th February 2013